Skip to main content
Clinical Trials/NCT02518685
NCT02518685
Completed
Not Applicable

Endoscopic Treatment for Weight Reduction in Patients With Obesity Using the TransPyloric Shuttle® System: A Multicenter, Prospective, Randomized, Double-Blind, Sham-Controlled, Parallel-Design Study

BaroNova, Inc.9 sites in 1 country302 target enrollmentSeptember 2015
ConditionsObesity

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Obesity
Sponsor
BaroNova, Inc.
Enrollment
302
Locations
9
Primary Endpoint
Mean Percent Total Body Weight Loss (% TBL) Between the TPS and the Control Group
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

The purpose of this clinical research trial is to study safety and effectiveness of the TransPyloric Shuttle System (TPSS) for weight reduction in patients who are considered medically obese.

Registry
clinicaltrials.gov
Start Date
September 2015
End Date
March 2018
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Male and female subjects between the ages of 22 to 60
  • A BMI between 30.0 to 40.0 kg/m2, inclusive. Subjects with a BMI of 30.0 kg/m2 to 34.9 kg/m2 are required to have one or more obesity-related comorbidities
  • History of obesity for at least 2 years, with history of failure of medically or commercially supervised weight loss program
  • \< 5% change in body weight for at least 3 months
  • Negative pregnancy test, agree to be on birth control for the duration of participation
  • Informed consent
  • Willing and able to comply with study procedures

Exclusion Criteria

  • Pregnancy or nursing
  • Hormonal or genetic cause for obesity
  • Prior history of any GI surgery or endoscopic intervention
  • Chronic use of medications likely to contribute to weight gain or prevent weight loss
  • Gastric or duodenal ulcers
  • Positive for H. pylori
  • History of severe dyspepsia
  • GI tract motility disorders
  • History of inflammatory disease of GI tract, coeliac disease, pancreatitis, portal hypertension, cirrhosis, and/or varices
  • Diabetes treated with insulin

Outcomes

Primary Outcomes

Mean Percent Total Body Weight Loss (% TBL) Between the TPS and the Control Group

Time Frame: 12 Months

The mean percent Total Body Weight Loss (% TBL) is the percentage weight change at 12 Months from Baseline

Proportion of TPS-treated Subjects With Weight Loss ≥ 5% TBL

Time Frame: 12 months

The proportion of subjects in the TPS group with ≥ 5% TBL is compared to a performance target of 50%

Study Sites (9)

Loading locations...

Similar Trials